The goal of this study is to pilot and evaluate a telemedicine medical abortion service delivery that allows remote communication between the woman and provider and limits medically unnecessary in-person visits to health or diagnostic centers.

The goal of this study is to pilot and evaluate a telemedicine medical abortion (TMA) service delivery that allows remote communication between the woman and provider and limits medically unnecessary in-person visits to health or diagnostic centers. Providers will provide counseling by phone or video about pregnancy options and give detailed information about the medical abortion process, expected side effects, and where to seek additional care. The provider will then evaluate the woman's eligibility for TMA service by following the no-test protocol and discuss at-home follow-up using a symptom checklist and a high-sensitivity urine pregnancy test. If pre-treatment tests are needed, women will be referred to a nearby diagnostic center and test results will be forwarded to the study provider. Participants will receive medications by mail or courier service or pick them up at the pharmacy or study clinics, take medications as instructed, and complete at-home follow-ups as discussed with the provider.

Inclusion Criteria:

• Is pregnant as determined by a pregnancy test or ultrasound (if obtained prior to contacting the study site)
• Has no contraindications to medical abortion
• Has access to a phone
• Is able to take mifepristone on or before 63 days of gestation

Exclusion Criteria:

• Medically ineligible for medical abortion
• Gestational age above 63 days based on LMP

Participants who seek early first-trimester abortion at the participating study site and would like to receive telemedicine medical abortion services.